dc.contributor
Institut Català de la Salut
dc.contributor
[Mansoor W] Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. [Joo S, Norquist JM] Merck & Co., Inc., Rahway, NJ, United States. [Kato K] Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. [Sun JM] Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. [Shah MA] Gastrointestinal Oncology Program, Weill Cornell Medical College, New York, NY, United States. [Alsina M] Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Mansoor, Wasat
dc.contributor.author
Joo, Seongjung
dc.contributor.author
Norquist, Josephine M
dc.contributor.author
Kato, Ken
dc.contributor.author
Sun, Jong-Mu
dc.contributor.author
Shah, Manish A.
dc.contributor.author
Alsina, Maria
dc.date.accessioned
2025-10-25T05:38:35Z
dc.date.available
2025-10-25T05:38:35Z
dc.date.issued
2024-10-08T09:38:37Z
dc.date.issued
2024-10-08T09:38:37Z
dc.identifier
Mansoor W, Joo S, Norquist JM, Kato K, Sun JM, Shah MA, et al. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer. Oncologist. 2024 Oct;29(10):e1324–35.
dc.identifier
https://hdl.handle.net/11351/12035
dc.identifier
10.1093/oncolo/oyae087
dc.identifier
001235033700001
dc.identifier.uri
http://hdl.handle.net/11351/12035
dc.description.abstract
Chemotherapy; Esophageal cancer; Health-related quality of life
dc.description.abstract
Quimioteràpia; Càncer d'esòfag; Qualitat de vida relacionada amb la salut
dc.description.abstract
Quimioterapia; Cáncer de esófago; Calidad de vida relacionada con la salud
dc.description.abstract
Background
In the KEYNOTE-590 study, first-line pembrolizumab plus chemotherapy provided statistically significant improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy, with a manageable safety profile in patients with advanced esophageal cancer. Prespecified health-related quality-of-life (HRQoL) outcomes are reported.
Materials and Methods
Change from baseline to week 18 in the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) global health status/QoL (GHS/QoL) and QLQ–Esophageal cancer module (OES18) dysphagia, pain, and reflux scales were evaluated.
Results
The HRQoL analysis included 730 patients who received treatment and completed ≥1 HRQoL assessment. Least squares mean (LSM) change from baseline to week 18 was similar between treatment groups for QLQ-C30 GHS/QoL and physical functioning and QLQ-OES18 reflux scales. The QLQ-OES18 dysphagia (LSM difference, −5.54; 95% CI, −10.93 to −0.16) and pain (LSM difference, −2.94; 95% CI, −5.86 to −0.02) scales favored pembrolizumab plus chemotherapy over placebo plus chemotherapy. Median time to confirmed deterioration (TTD) was similar between treatment groups for QLQ-C30 GHS/QoL and physical functioning and QLQ-OES18 dysphagia and reflux scales. Compared with chemotherapy, pembrolizumab plus chemotherapy prolonged median TTD, as seen on the QLQ-OES18 pain scale (HR, 0.69; 95% CI, 0.51 to 0.95).
Conclusion
The use of pembrolizumab plus chemotherapy maintained HRQoL at week 18 relative to baseline and was comparable with placebo plus chemotherapy. These HRQoL results together with published reports of efficacy, support the use of pembrolizumab plus chemotherapy as first-line therapy for advanced/metastatic esophageal cancer.
ClinicalTrials.gov ID
NCT03189719
dc.description.abstract
Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
dc.format
application/pdf
dc.publisher
Oxford University Press
dc.relation
The Oncologist;29(10)
dc.relation
https://doi.org/10.1093/oncolo/oyae087
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Qualitat de vida - Avaluació
dc.subject
Esòfag - Càncer - Tractament
dc.subject
Quimioteràpia combinada
dc.subject
Anticossos monoclonals - Ús terapèutic
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Esophageal Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias del esófago
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida
dc.title
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
